Fsd Pharma Inc Subordinate Voting Share (HUGE-CN) Press Releases

Delayed Last Update

Volume

Latest News

FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Newsfile - Sun Apr 7, 10:00PM CDT

Newsfile

Sun Apr 7, 10:00PM CDT

Toronto, Ontario--(Newsfile Corp. - April 7, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that on April 5, 2024 it...

FSD Pharma Announces US ATM Offering

ACCESSWIRE - Fri Feb 16, 6:10PM CST

ACCESSWIRE

Fri Feb 16, 6:10PM CST

TORONTO, ON / ACCESSWIRE / February 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased...

FSD Pharma Inc. Announces Closing of Private Placement

ACCESSWIRE - Tue Dec 5, 2023

ACCESSWIRE

Tue Dec 5, 2023

TORONTO, ON / ACCESSWIRE / December 5, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (the "Company" or "FSD"), is pleased to announce that, further to its news release on November 27, 2023, it has closed a non-brokered private placement...

FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement

ACCESSWIRE - Thu Nov 30, 2023

ACCESSWIRE

Thu Nov 30, 2023

TORONTO, ON / ACCESSWIRE / November 30, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company) and Celly Nutrition Corp. ("Celly Nu") are pleased to announce the closing of the previously announced proposed...

Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness

ACCESSWIRE - Tue Nov 28, 2023

ACCESSWIRE

Tue Nov 28, 2023

TORONTO, ON / ACCESSWIRE / November 28, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions. The...

FSD Pharma Inc. Obtains Final Order for Plan of Arrangement

ACCESSWIRE - Mon Nov 27, 2023

ACCESSWIRE

Mon Nov 27, 2023

TORONTO, ON / ACCESSWIRE / November 27, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased...

Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.

ACCESSWIRE - Fri Nov 24, 2023

ACCESSWIRE

Fri Nov 24, 2023

BALTIMORE, MD / ACCESSWIRE / November 24, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on FSD Pharma, Inc....

FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.

ACCESSWIRE - Tue Nov 21, 2023

ACCESSWIRE

Tue Nov 21, 2023

TORONTO, ON / ACCESSWIRE / November 21, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased...

FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement

ACCESSWIRE - Fri Nov 17, 2023

ACCESSWIRE

Fri Nov 17, 2023

TORONTO, ON / ACCESSWIRE / November 17, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased...

FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023

ACCESSWIRE - Wed Nov 15, 2023

ACCESSWIRE

Wed Nov 15, 2023

TORONTO, ON / ACCESSWIRE / November 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,is pleased...

FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One Basis

ACCESSWIRE - Tue Nov 7, 2023

ACCESSWIRE

Tue Nov 7, 2023

TORONTO, ON / ACCESSWIRE / November 7, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,is pleased to...

FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus

ACCESSWIRE - Mon Nov 6, 2023

ACCESSWIRE

Mon Nov 6, 2023

TORONTO, ON / ACCESSWIRE / November 6, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased...

FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly Nu

ACCESSWIRE - Mon Oct 23, 2023

ACCESSWIRE

Mon Oct 23, 2023

TORONTO, ON / ACCESSWIRE / October 23, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, and Celly...

FSD Pharma and Celly Nu Enter Into Arrangement Agreement

ACCESSWIRE - Thu Oct 5, 2023

ACCESSWIRE

Thu Oct 5, 2023

TORONTO, ON / ACCESSWIRE / October 5, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, and Celly...

FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice

ACCESSWIRE - Wed Oct 4, 2023

ACCESSWIRE

Wed Oct 4, 2023

TORONTO, ON / ACCESSWIRE / October 4, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the...

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated

ACCESSWIRE - Mon Sep 18, 2023

ACCESSWIRE

Mon Sep 18, 2023

TORONTO, ON / ACCESSWIRE / September 18, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the...

FSD Pharma Announces Analyst Coverage Initiated by Singular Research

ACCESSWIRE - Wed Sep 13, 2023

ACCESSWIRE

Wed Sep 13, 2023

TORONTO, ON / ACCESSWIRE / September 13, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the...

FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023

ACCESSWIRE - Tue Aug 15, 2023

ACCESSWIRE

Tue Aug 15, 2023

Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market

FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink

ACCESSWIRE - Wed Aug 2, 2023

ACCESSWIRE

Wed Aug 2, 2023

Launch in the Consumer Market to be Led by Former Executives from Coca-Cola and Celsius Holdings

DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLION

Newswire.ca - Wed Jun 21, 2023

Newswire.ca

Wed Jun 21, 2023

/CNW/ -- Attorneys for Dr. Raza Bokhari, the former CEO and Executive Chairman of FSD Pharma (CSE: HUGE, NASDAQ: HUGE) have filed two new claims against his...

FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11

Business Wire - Mon May 8, 2023

Business Wire

Mon May 8, 2023

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging...

FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis

Business Wire - Mon Apr 17, 2023

Business Wire

Mon Apr 17, 2023

FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023

Business Wire - Wed Apr 12, 2023

Business Wire

Wed Apr 12, 2023

FSD Pharma Announces Filing of Year-End 2022 Results

Business Wire - Fri Mar 31, 2023

Business Wire

Fri Mar 31, 2023